

Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Growth 2023-2029

<https://marketpublishers.com/r/G4447A76AE3EEN.html>

Date: January 2023

Pages: 124

Price: US\$ 3,660.00 (Single User License)

ID: G4447A76AE3EEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

LPI (LP Information)' newest research report, the “Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Industry Forecast” looks at past sales and reviews total world Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) sales in 2022, providing a comprehensive analysis by region and market sector of projected Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) sales for 2023 through 2029. With Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Granulocyte Colony-Stimulating

Factor Injection (rhG-CSF) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF).

The global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) players cover Abbott, Amgen, Arven Pharmaceuticals, Biocon, Cadila Pharmaceuticals, Dr.Reddy's Laboratories, Emcure Pharmaceuticals, Intas Pharmaceuticals and Kyowa Kirin, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Vials

Prefilled

Segmentation by application

Myelosuppressive Chemotherapy

Leukemia Chemotherapy

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Abbott

Amgen

Arven Pharmaceuticals

Biocon

Cadila Pharmaceuticals

Dr.Reddy's Laboratories

Emcure Pharmaceuticals

Intas Pharmaceuticals

Kyowa Kirin

Novartis

Pfizer

Reliance Life Sciences

Harbin Pharmaceutical

North China Pharmaceutical

Jiuyuan Gene

Kexing Biopharm

Qilu Pharmaceutical

Quangang Pharmaceutical

Sunway Biotech

SL Pharmaceutical

Four Rings Bio-Pharmaceutical

Amoytop

Wuzhong Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market?

What factors are driving Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market opportunities vary by end market size?

How does Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Annual Sales 2018-2029

2.1.2 World Current & Future Analysis for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Geographic Region, 2018, 2022 & 2029

2.1.3 World Current & Future Analysis for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Country/Region, 2018, 2022 & 2029

2.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Segment by Type

2.2.1 Vials

2.2.2 Prefilled

2.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type

2.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Type (2018-2023)

2.3.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue and Market Share by Type (2018-2023)

2.3.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sale Price by Type (2018-2023)

2.4 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Segment by Application

2.4.1 Myelosuppressive Chemotherapy

2.4.2 Leukemia Chemotherapy

2.4.3 Others

2.5 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application

2.5.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sale Market Share by Application (2018-2023)

2.5.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue and Market Share by Application (2018-2023)

2.5.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sale Price by Application (2018-2023)

3 GLOBAL RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR INJECTION (RHG-CSF) BY COMPANY

3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Breakdown Data by Company

3.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Annual Sales by Company (2018-2023)

3.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Company (2018-2023)

3.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Annual Revenue by Company (2018-2023)

3.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Company (2018-2023)

3.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Company (2018-2023)

3.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sale Price by Company

3.4 Key Manufacturers Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Location Distribution

3.4.2 Players Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR RECOMBINANT HUMAN GRANULOCYTE

COLONY-STIMULATING FACTOR INJECTION (RHG-CSF) BY GEOGRAPHIC REGION

4.1 World Historic Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Geographic Region (2018-2023)

4.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country/Region (2018-2023)

4.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Annual Sales by Country/Region (2018-2023)

4.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Annual Revenue by Country/Region (2018-2023)

4.3 Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Growth

4.4 APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Growth

4.5 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Growth

4.6 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Growth

5 AMERICAS

5.1 Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country

5.1.1 Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2023)

5.1.2 Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2023)

5.2 Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type

5.3 Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region

6.1.1 APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region (2018-2023)

6.1.2 APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region (2018-2023)

6.2 APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type

6.3 APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Country

7.1.1 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2023)

7.1.2 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2023)

7.2 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type

7.3 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Country

8.1.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2023)

8.1.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2023)

8.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type

8.3 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)

10.3 Manufacturing Process Analysis of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)

10.4 Industry Chain Structure of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
Distributors

11.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
Customer

12 WORLD FORECAST REVIEW FOR RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR INJECTION (RHG-CSF) BY GEOGRAPHIC REGION

12.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size Forecast by Region

12.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Forecast by Region (2024-2029)

12.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Forecast by Type

12.7 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Abbott

13.1.1 Abbott Company Information

13.1.2 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.1.3 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 Abbott Main Business Overview

13.1.5 Abbott Latest Developments

13.2 Amgen

13.2.1 Amgen Company Information

13.2.2 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.2.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Amgen Main Business Overview

13.2.5 Amgen Latest Developments

13.3 Arven Pharmaceuticals

13.3.1 Arven Pharmaceuticals Company Information

13.3.2 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.3.3 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Arven Pharmaceuticals Main Business Overview

13.3.5 Arven Pharmaceuticals Latest Developments

13.4 Biocon

13.4.1 Biocon Company Information

13.4.2 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.4.3 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Biocon Main Business Overview

13.4.5 Biocon Latest Developments

13.5 Cadila Pharmaceuticals

13.5.1 Cadila Pharmaceuticals Company Information

13.5.2 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.5.3 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Cadila Pharmaceuticals Main Business Overview

13.5.5 Cadila Pharmaceuticals Latest Developments

13.6 Dr.Reddy's Laboratories

13.6.1 Dr.Reddy's Laboratories Company Information

13.6.2 Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.6.3 Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Dr.Reddy's Laboratories Main Business Overview

13.6.5 Dr.Reddy's Laboratories Latest Developments

13.7 Emcure Pharmaceuticals

13.7.1 Emcure Pharmaceuticals Company Information

13.7.2 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating

Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.7.3 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Emcure Pharmaceuticals Main Business Overview

13.7.5 Emcure Pharmaceuticals Latest Developments

13.8 Intas Pharmaceuticals

13.8.1 Intas Pharmaceuticals Company Information

13.8.2 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.8.3 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 Intas Pharmaceuticals Main Business Overview

13.8.5 Intas Pharmaceuticals Latest Developments

13.9 Kyowa Kirin

13.9.1 Kyowa Kirin Company Information

13.9.2 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.9.3 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 Kyowa Kirin Main Business Overview

13.9.5 Kyowa Kirin Latest Developments

13.10 Novartis

13.10.1 Novartis Company Information

13.10.2 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.10.3 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 Novartis Main Business Overview

13.10.5 Novartis Latest Developments

13.11 Pfizer

13.11.1 Pfizer Company Information

13.11.2 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.11.3 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 Pfizer Main Business Overview

13.11.5 Pfizer Latest Developments

13.12 Reliance Life Sciences

13.12.1 Reliance Life Sciences Company Information

- 13.12.2 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications
- 13.12.3 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.12.4 Reliance Life Sciences Main Business Overview
- 13.12.5 Reliance Life Sciences Latest Developments
- 13.13 Harbin Pharmaceutical
 - 13.13.1 Harbin Pharmaceutical Company Information
 - 13.13.2 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications
 - 13.13.3 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.13.4 Harbin Pharmaceutical Main Business Overview
 - 13.13.5 Harbin Pharmaceutical Latest Developments
- 13.14 North China Pharmaceutical
 - 13.14.1 North China Pharmaceutical Company Information
 - 13.14.2 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications
 - 13.14.3 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.14.4 North China Pharmaceutical Main Business Overview
 - 13.14.5 North China Pharmaceutical Latest Developments
- 13.15 Jiuyuan Gene
 - 13.15.1 Jiuyuan Gene Company Information
 - 13.15.2 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications
 - 13.15.3 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.15.4 Jiuyuan Gene Main Business Overview
 - 13.15.5 Jiuyuan Gene Latest Developments
- 13.16 Kexing Biopharm
 - 13.16.1 Kexing Biopharm Company Information
 - 13.16.2 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications
 - 13.16.3 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.16.4 Kexing Biopharm Main Business Overview
 - 13.16.5 Kexing Biopharm Latest Developments

13.17 Qilu Pharmaceutical

13.17.1 Qilu Pharmaceutical Company Information

13.17.2 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.17.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.17.4 Qilu Pharmaceutical Main Business Overview

13.17.5 Qilu Pharmaceutical Latest Developments

13.18 Quangang Pharmaceutical

13.18.1 Quangang Pharmaceutical Company Information

13.18.2 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.18.3 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.18.4 Quangang Pharmaceutical Main Business Overview

13.18.5 Quangang Pharmaceutical Latest Developments

13.19 Sunway Biotech

13.19.1 Sunway Biotech Company Information

13.19.2 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.19.3 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.19.4 Sunway Biotech Main Business Overview

13.19.5 Sunway Biotech Latest Developments

13.20 SL Pharmaceutical

13.20.1 SL Pharmaceutical Company Information

13.20.2 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.20.3 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.20.4 SL Pharmaceutical Main Business Overview

13.20.5 SL Pharmaceutical Latest Developments

13.21 Four Rings Bio-Pharmaceutical

13.21.1 Four Rings Bio-Pharmaceutical Company Information

13.21.2 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.21.3 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin

(2018-2023)

13.21.4 Four Rings Bio-Pharmaceutical Main Business Overview

13.21.5 Four Rings Bio-Pharmaceutical Latest Developments

13.22 Amoytop

13.22.1 Amoytop Company Information

13.22.2 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.22.3 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.22.4 Amoytop Main Business Overview

13.22.5 Amoytop Latest Developments

13.23 Wuzhong Pharmaceutical

13.23.1 Wuzhong Pharmaceutical Company Information

13.23.2 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

13.23.3 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue, Price and Gross Margin (2018-2023)

13.23.4 Wuzhong Pharmaceutical Main Business Overview

13.23.5 Wuzhong Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Vials

Table 4. Major Players of Prefilled

Table 5. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type (2018-2023) & (K L)

Table 6. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Type (2018-2023)

Table 7. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Type (2018-2023) & (\$ million)

Table 8. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Type (2018-2023)

Table 9. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sale Price by Type (2018-2023) & (US\$/L)

Table 10. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application (2018-2023) & (K L)

Table 11. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Application (2018-2023)

Table 12. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Application (2018-2023)

Table 13. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Application (2018-2023)

Table 14. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sale Price by Application (2018-2023) & (US\$/L)

Table 15. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Company (2018-2023) & (K L)

Table 16. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Company (2018-2023)

Table 17. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Company (2018-2023) (\$ Millions)

Table 18. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Company (2018-2023)

Table 19. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection

(rhG-CSF) Sale Price by Company (2018-2023) & (US\$/L)

Table 20. Key Manufacturers Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Producing Area Distribution and Sales Area

Table 21. Players Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Products Offered

Table 22. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Geographic Region (2018-2023) & (K L)

Table 26. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share Geographic Region (2018-2023)

Table 27. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 28. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Geographic Region (2018-2023)

Table 29. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country/Region (2018-2023) & (K L)

Table 30. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Country/Region (2018-2023)

Table 31. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country/Region (2018-2023) & (\$ millions)

Table 32. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Country/Region (2018-2023)

Table 33. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2023) & (K L)

Table 34. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Country (2018-2023)

Table 35. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2023) & (\$ Millions)

Table 36. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Country (2018-2023)

Table 37. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type (2018-2023) & (K L)

Table 38. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application (2018-2023) & (K L)

Table 39. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region (2018-2023) & (K L)

- Table 40. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Region (2018-2023)
- Table 41. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region (2018-2023) & (\$ Millions)
- Table 42. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Region (2018-2023)
- Table 43. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type (2018-2023) & (K L)
- Table 44. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application (2018-2023) & (K L)
- Table 45. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2023) & (K L)
- Table 46. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Country (2018-2023)
- Table 47. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2023) & (\$ Millions)
- Table 48. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Country (2018-2023)
- Table 49. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type (2018-2023) & (K L)
- Table 50. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application (2018-2023) & (K L)
- Table 51. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2023) & (K L)
- Table 52. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Country (2018-2023)
- Table 53. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2023) & (\$ Millions)
- Table 54. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Country (2018-2023)
- Table 55. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type (2018-2023) & (K L)
- Table 56. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application (2018-2023) & (K L)
- Table 57. Key Market Drivers & Growth Opportunities of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
- Table 58. Key Market Challenges & Risks of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
- Table 59. Key Industry Trends of Recombinant Human Granulocyte Colony-Stimulating

Factor Injection (rhG-CSF)

Table 60. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Raw Material

Table 61. Key Suppliers of Raw Materials

Table 62. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Distributors List

Table 63. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Customer List

Table 64. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Forecast by Region (2024-2029) & (K L)

Table 65. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 66. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Forecast by Country (2024-2029) & (K L)

Table 67. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 68. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Forecast by Region (2024-2029) & (K L)

Table 69. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 70. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Forecast by Country (2024-2029) & (K L)

Table 71. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 72. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Forecast by Country (2024-2029) & (K L)

Table 73. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 74. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Forecast by Type (2024-2029) & (K L)

Table 75. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 76. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Forecast by Application (2024-2029) & (K L)

Table 77. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 78. Abbott Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 79. Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 80. Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 81. Abbott Main Business

Table 82. Abbott Latest Developments

Table 83. Amgen Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 84. Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 85. Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 86. Amgen Main Business

Table 87. Amgen Latest Developments

Table 88. Arven Pharmaceuticals Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 89. Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 90. Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 91. Arven Pharmaceuticals Main Business

Table 92. Arven Pharmaceuticals Latest Developments

Table 93. Biocon Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 94. Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 95. Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 96. Biocon Main Business

Table 97. Biocon Latest Developments

Table 98. Cadila Pharmaceuticals Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its

Competitors

Table 99. Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 100. Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 101. Cadila Pharmaceuticals Main Business

Table 102. Cadila Pharmaceuticals Latest Developments

Table 103. Dr.Reddy's Laboratories Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 104. Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 105. Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 106. Dr.Reddy's Laboratories Main Business

Table 107. Dr.Reddy's Laboratories Latest Developments

Table 108. Emcure Pharmaceuticals Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 109. Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 110. Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 111. Emcure Pharmaceuticals Main Business

Table 112. Emcure Pharmaceuticals Latest Developments

Table 113. Intas Pharmaceuticals Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 114. Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 115. Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 116. Intas Pharmaceuticals Main Business

Table 117. Intas Pharmaceuticals Latest Developments

Table 118. Kyowa Kirin Basic Information, Recombinant Human Granulocyte Colony-

Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 119. Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 120. Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 121. Kyowa Kirin Main Business

Table 122. Kyowa Kirin Latest Developments

Table 123. Novartis Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 124. Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 125. Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 126. Novartis Main Business

Table 127. Novartis Latest Developments

Table 128. Pfizer Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 129. Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 130. Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 131. Pfizer Main Business

Table 132. Pfizer Latest Developments

Table 133. Reliance Life Sciences Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 134. Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 135. Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 136. Reliance Life Sciences Main Business

Table 137. Reliance Life Sciences Latest Developments

Table 138. Harbin Pharmaceutical Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 139. Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 140. Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 141. Harbin Pharmaceutical Main Business

Table 142. Harbin Pharmaceutical Latest Developments

Table 143. North China Pharmaceutical Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 144. North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 145. North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 146. North China Pharmaceutical Main Business

Table 147. North China Pharmaceutical Latest Developments

Table 148. Jiuyuan Gene Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 149. Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 150. Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 151. Jiuyuan Gene Main Business

Table 152. Jiuyuan Gene Latest Developments

Table 153. Kexing Biopharm Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 154. Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 155. Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 156. Kexing Biopharm Main Business

Table 157. Kexing Biopharm Latest Developments

Table 158. Qilu Pharmaceutical Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 159. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 160. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 161. Qilu Pharmaceutical Main Business

Table 162. Qilu Pharmaceutical Latest Developments

Table 163. Quangang Pharmaceutical Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 164. Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 165. Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 166. Quangang Pharmaceutical Main Business

Table 167. Quangang Pharmaceutical Latest Developments

Table 168. Sunway Biotech Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 169. Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 170. Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 171. Sunway Biotech Main Business

Table 172. Sunway Biotech Latest Developments

Table 173. SL Pharmaceutical Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 174. SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 175. SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 176. SL Pharmaceutical Main Business

Table 177. SL Pharmaceutical Latest Developments

Table 178. Four Rings Bio-Pharmaceutical Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 179. Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 180. Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 181. Four Rings Bio-Pharmaceutical Main Business

Table 182. Four Rings Bio-Pharmaceutical Latest Developments

Table 183. Amoytop Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 184. Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 185. Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 186. Amoytop Main Business

Table 187. Amoytop Latest Developments

Table 188. Wuzhong Pharmaceutical Basic Information, Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Base, Sales Area and Its Competitors

Table 189. Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolios and Specifications

Table 190. Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (\$ Million), Price (US\$/L) and Gross Margin (2018-2023)

Table 191. Wuzhong Pharmaceutical Main Business

Table 192. Wuzhong Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)

Figure 2. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Growth Rate 2018-2029 (K L)

Figure 7. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate 2018-2029 (\$ Millions)

Figure 8. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region (2018, 2022 & 2029) & (\$ Millions)

Figure 9. Product Picture of Vials

Figure 10. Product Picture of Prefilled

Figure 11. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Type in 2022

Figure 12. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Type (2018-2023)

Figure 13. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumed in Myelosuppressive Chemotherapy

Figure 14. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Myelosuppressive Chemotherapy (2018-2023) & (K L)

Figure 15. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumed in Leukemia Chemotherapy

Figure 16. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Leukemia Chemotherapy (2018-2023) & (K L)

Figure 17. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumed in Others

Figure 18. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Others (2018-2023) & (K L)

Figure 19. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Application (2022)

Figure 20. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Application in 2022

- Figure 21. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market by Company in 2022 (K L)
- Figure 22. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Company in 2022
- Figure 23. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market by Company in 2022 (\$ Million)
- Figure 24. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Company in 2022
- Figure 25. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Geographic Region (2018-2023)
- Figure 26. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Geographic Region in 2022
- Figure 27. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales 2018-2023 (K L)
- Figure 28. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue 2018-2023 (\$ Millions)
- Figure 29. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales 2018-2023 (K L)
- Figure 30. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue 2018-2023 (\$ Millions)
- Figure 31. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales 2018-2023 (K L)
- Figure 32. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue 2018-2023 (\$ Millions)
- Figure 33. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales 2018-2023 (K L)
- Figure 34. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue 2018-2023 (\$ Millions)
- Figure 35. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Country in 2022
- Figure 36. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Country in 2022
- Figure 37. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Type (2018-2023)
- Figure 38. Americas Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Application (2018-2023)
- Figure 39. United States Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth 2018-2023 (\$ Millions)
- Figure 40. Canada Recombinant Human Granulocyte Colony-Stimulating Factor

Injection (rhG-CSF) Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Mexico Recombinant Human Granulocyte Colony-Stimulating Factor

Injection (rhG-CSF) Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Brazil Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth 2018-2023 (\$ Millions)

Figure 43. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Region in 2022

Figure 44. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Regions in 2022

Figure 45. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Type (2018-2023)

Figure 46. APAC Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Application (2018-2023)

Figure 47. China Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth 2018-2023 (\$ Millions)

Figure 48. Japan Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth 2018-2023 (\$ Millions)

Figure 49. South Korea Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth 2018-2023 (\$ Millions)

Figure 50. Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth 2018-2023 (\$ Millions)

Figure 51. India Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth 2018-2023 (\$ Millions)

Figure 52. Australia Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth 2018-2023 (\$ Millions)

Figure 53. China Taiwan Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth 201

I would like to order

Product name: Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G4447A76AE3EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4447A76AE3EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

